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Message from the Vice President, Aurora Cancer Care
Aurora Health Care employs over

James Weese, MD, FACS
Vice President,
Aurora Cancer Care

33,000 caregivers, making it the
largest private employer in Wisconsin.
Aurora Cancer Care has many of the
very best caregivers. For this reason,
we wanted to be able to recognize
exemplary work in taking care of our
nearly 8,000 new cancer patients
each year.

The fourth award was given to an individual. There were
many excellent nominees for each award.
The team award for performance improvement with
positive measurable outcomes was given to Anne Weers,
Dorry Mitchell, Zarina Dawoodbhai, Rita Wilbert and Kevin
Clement for “Improving Referral Capture and Tracking
Outcomes of Lung CT program.” Part of our population
health initiative, this program extends across the system
and is doubling the number of patients who meet criteria
for screening each year. Of those high-risk patients, about
two percent are found to have lung cancer—many when the
cancer is still early and highly curable.

This year, I was asked to serve on the
VIA Oncology Board of Managers.
I am the only member not affiliated
The team award for a Patient or Caregiver Safety Initiative
with the University of Pittsburgh. A generous stipend
was given to Brenda Mauer, Kerry Twite and Peter Stuessy
comes with this position and I turn this over to the Aurora
for ”Rate/time Infusion Process Change for Oxaliplatin.”
Foundation. With these dollars, we have established three
team awards and one individual award for outstanding
The award to an interdisciplinary team that developed a
services. We have named them as the Marija Bjegovichpatient-centered program or service was given to Ana
Weidman awards
Farnsworth, Angi
for Excellence in
Paradowski, Tracy
Oncology in honor of
Batcher and Jennifer
Marija, who stepped
Wiesmueller for
down this year as the
“Development of
Senior Director of
a Sarcoma MDC
Aurora Cancer Care.
(Multidisciplinary
Marija has been with
Clinic).”
Aurora for over 35
The award for
years and has been
Individual Excellence
a major force behind
was given to Kerry
ACC’s success. The
Twite for “Oncology
awards fall into four
Nursing Education.”
categories; the first
three were each given
to teams of five or
continued on page 2
ACC Caregiver Awards, pictured left to right: Marija Bjegovich-Weidman, Dr. Jim Weese,
fewer caregivers.
Peter Stuessy, Kerry Twite, Carol Huibregtse, Dr. Nick Turkal.

Message from the Vice President... continued
Each of these awards was presented by Dr. Nick Turkal, CEO of Aurora
Health Care, after his introductory remarks. The awards also come with a
generous stipend.
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To make the awards complete, Marija Bjegovich-Weidman was presented
with an award for her many years of service and contributions to Aurora
Cancer Care and the above awards were presented in her honor at the
annual all-oncology dinner on September 18, 2017. ■

Helpful documents for joint decision
making for prostate screening
James Weese, MD, FACS Vice President, Aurora Cancer Care

In 2012, the U.S. Preventive Services Task Force (USPSTF) put out a

statement that there was no evidence to justify screening (using PSA or
digital rectal exam) in men to detect prostate cancer. Unfortunately, this
recommendation was based on flawed data and had several subsequent
effects. A number of insurance carriers stopped covering PSA testing
and many physicians stopped encouraging men to undergoing screening.
This resulted in significant concern from multiple constituencies, but the
guidelines remained until recently. Part of this was due to the concern that
large numbers of patients were undergoing robotic prostatectomy because
of the blossoming availability of the new technology and innovative forms of
radiation therapy and there were no generally accepted guidelines to define
which patients should undergo the procedure.
Many physicians remembered the time before screening when patients were
diagnosed with prostate cancer after the disease had metastasized and was
incurable. National statistics suggested the five-year survival for patients
diagnosed with localized disease was approximately 90 percent compared to
less than 40 percent if the disease had spread.

During this time, Aurora Cancer Care, in collaboration with our Urologists,
Medical Oncologists and Radiation Oncologists, established the
multidisciplinary GU Cancer Conference. As a group, patients were presented
before undergoing radical prostatectomy and those patients with highergrade tumors were recommended for aggressive therapy (robotic or open
prostatectomy or radiation therapy). Those with less aggressive tumors were
followed with careful observation. Additional concern was raised by review
of the National Cancer Data Base of the Commission on Cancer.
Between 2011 and 2014, there was a concerning stage migration
where the percentage of stage I and II prostate cancer fell from
Men ages
82 percent to 76.8 percent of newly diagnosed prostate cancer
patients and the stage III and IV incidence rose from 14.1 percent
to 20.8 percent. This was on a national pool of nearly 190,000
should make an
patients diagnosed during those four years. Reviewing Aurora
individualized
Cancer Registry statistics, between 2012 and 2016 the percentage
of stage I and II fell from 81.1 percent to 74.3 percent and stage III
decision about
and IV increased from 17.3 percent to 22.6 percent.

55-69

prostate
cancer
screening

in consultation
with their clinician.
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Of interest, this year the USPSTF revised their recommendations
to “men ages 55-69 should make an individualized decision
about prostate cancer screening with their clinician.” As a result,
a committee made up of Urologists and Primary Care Physicians
have developed documents providing information to physicians
and their patients. These are available in EPIC and have been
approved by the Primary Care Leadership Council, the Urologists
and the Cancer Leadership Council. ■

Oncology Precision Medicine Program update
Precision medicine—relying on molecular profiling of a patient’s tumor—is becoming increasingly

important in cancer treatment. With this in mind, Aurora Cancer Care launched a Molecular Tumor
Board and Oncology Precision Medicine Clinic in March 2017. Our initial goal was to evaluate 50
patients during the first year—a goal we exceeded within the first four months.
Molecular Tumor Board
Each Friday morning, participating
members from around the state use
video technology to join in discussion
that centers on finding treatments for
patients based on molecular profiling
results. Our team consists of members
from medical oncology, surgical oncology,
radiation oncology, pathology, pharmacy,
genetic counseling and research.
In November, we completed review
of our 100th patient in a
multidisciplinary fashion.

OPeN is a proposed data-sharing network that would bring
together Precision Medicine patient experiences from
multiple organizations. Using this software, our providers
can access de-identified patients with similar molecular
characteristics and review what treatments they received
and how they responded. Our Precision Medicine team
recently attended the inaugural OPeN network meeting
in Zion National Park. Also attending were Intermountain
Healthcare, Stanford, Catholic Health Initiatives, University
of Miami and Henry Ford, among others. We were given
the opportunity to present the Aurora Precision Medicine
experience and learn from other organizations. It also was a
chance to direct how we would like the network to function
for our caregivers.

Oncology Precision Medicine Clinic
Medical oncologists Mike Thompson, MD, PhD, and Tony
Ruggeri, MD, meet with patients at the Aurora St. Luke’s
Medical Center Vince Lombardi Cancer Clinic each Friday.
Patients are referred by their primary oncologist for
facilitation of precision medicine testing. During these
visits our team provides patient education, coordination
of biopsies or tissue acquisition, facilitation of financial
aid paperwork, submission of molecular testing forms
and help with drug acquisition.

Conclusion
The Aurora Oncology Precision Medicine program has had a
successful first six months thanks in large part to excellent
collaboration from providers and caregivers throughout the
system. We thank you for your support and look forward
to working with you to continue to offer this important
treatment option to the patients of Aurora Cancer Care.

Outcomes and Metrics Generation
We are working to quantify the impact made by the
Precision Medicine team in the care of our patients.
We have created a dashboard to visually display metrics
(see charts). We plan to collect and share additional
outcomes including the number of patients with an
actionable genetic variant,
the number of patients
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The Precision Medicine
team has been working
closely with Aurora’s EPIC
team to integrate Syapse,
a Precision Medicine
software platform, with
our electronic medical
record. The program will
go live for all medical
oncologists in November.
Syapse provides a platform
for viewing of molecular
panel test results, as well
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If you would like us to coordinate
molecular panel testing for a
patient, please place a “Service
to Oncology Precision Medicine”
referral in EPIC.
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If you have a patient with molecular profiling results you
would like to submit for discussion, please send a staff
message through EPIC to SLM ONC Precision Medicine
Consult Pool.

Thompson

Jen Godden,
PharmD, BCOP
Specialty Pharmacy
Coordinator,
Oncology
Pharmacogenomics
Co-Director, Aurora
Oncology Precision
Medicine Program

as functionality for organizing Molecular Tumor Board
discussion and recommendations. A significant advantage
of the program will be future access to the Oncology
Precision Network (OPeN) network.

See the Aurora Health Care
blog for more information
about the program: http://ow.ly/
c0Jx30bald6
We have also published on
our experience setting up the
program: Implementing an
Oncology Precision Medicine
Clinic in a Large Community
Health System http://ow.ly/
DYBk30ehyr8 ■
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Hereditary Cancer Prevention and
Management Center at ASLMC and ABMC
The Aurora Hereditary Cancer

Prevention and Management Center
(HCPMC) was established in May 2015
by oncologist Michael Mullane, MD, and
Deborah Wham, MS, CGC. The concept of
the clinic is to provide continuity of care
for individuals and families with complex
Deborah Wham,
or difficult hereditary cancer conditions.
MS, CGC
Michael Mullane, MD, and the Aurora
Manager, Certified
Genetic Counselor
Genomic Medicine Department have
Genomic Medicine
collaborated to establish this program
Program Aurora
aimed at providing preventive care to the
Health Care
highest-risk individuals. At the Aurora
HCPMC, patients and at-risk relatives undergo an evaluation
and discuss management and prevention recommendations.
This clinic is the first of its kind in the Midwest and
continues to be the model for health care organizations
looking to establish hereditary cancer management clinics
around the country. For example, Dr. Mullane was asked
to give a lecture about the concept and execution of the
HCPMC in June 2017 at the annual American Society of
Clinical Oncology meeting. Additionally, Deborah Wham,
certified genetic counselor and manager of the Genomic
Medicine Program presented a poster at the National
Society of Genetic Counselors conference in September
2017 with outcomes from the HCPMC.

Many patients required ongoing surveillance, including
serial imaging studies, laboratory tests, referrals to other
specialists and some further genetic testing.
Figure 1. Medical Management for all patients
May 2015-May 2017

The clinic is designed specifically to address the needs of
patients with rare and complicated cancer risks. Patients
with a single gene mutation tend to have multi-organ
system risks. Additionally, in the first two years, patients
with risks associated with 25 different genes were seen
and evaluated. ■
Figure 2.

Since its inception, Aurora has gone from a twice-amonth clinic to a weekly clinic. It is now available at
Aurora St. Luke’s Medical Center and Aurora BayCare
Medical Center. In the first two years, 186 patients were
seen in the clinic. Fifty-five of these patients were family
members of the initial patient found to have the disease/
gene mutation. Medical management and surveillance
plans were initiated for appropriate patients. These plans
were tailored to the individual and family according to the
cancer risks associated with their particular gene mutation.

Although the HCPMC is a relatively new clinic, the medical management plans implemented have already yielded
some important outcomes. Four cases are described here.
Age 33 unaffected male reluctantly came to HCPMC after his mother was found to have a CDH1 mutation. He tested
positive for the familial mutation. We referred him to GI surgical oncology for prophylactic gastrectomy. He was found
to have stage I diffuse gastric cancer, and required no further treatment.
Age 37 unaffected female came to HCPMC after testing positive for a familial SDHB mutation. Screening was initiated
including whole body MRI, which revealed a 2.5cm carotid body paraganglioma. Surgery pending.
Age 44 female found to have a PTEN mutation after a breast cancer diagnosis and treatment. She came to the HCPMC
after a colonoscopy revealed harmartomatous polyposis and GI recommended colectomy. We found a GI willing to do
serial colonoscopy. We initiated high risk breast screening. A second primary breast cancer was found.
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Age 43 female came to the HCPMC after she was identified to have 2 different TP53 mutations, detected at low allele
frequencies. She had been given a diagnosis of Li Fraumeni prior to coming to our clinic. We initiated a confirmatory
algorithm including cascade testing of children, single site testing in skin fibroblasts, normal breast tissue and cancerous
breast tissue. Both mutations were found only in tumor specimen. Thus, the diagnosis of Li Fraumeni was disproven.

Aurora Health Care treats more lung cancer than
any other health care system in Wisconsin—
Highlights of the Thoracic Cancer Surgery Program
Anne Weers, RN, MS System Program Quality Manager, Aurora Cancer Care

Aurora Health Care (AHC) treats 1 out of every 4 lung

cancer patients in Wisconsin. Our multidisciplinary
team brings together a group of dedicated lung cancer
specialists to provide personalized care, including
thoracic surgeons who specialize in lung cancer
surgery, pulmonologists, medical oncologists, radiation
oncologists, cancer care coordinators, dieticians, cancer
rehabilitation specialists and cancer nurse navigators. Our
comprehensive program offers cutting-edge techniques
and screenings for patients throughout the country. For
example, in 2016, Aurora Grafton, Aurora St. Luke’s and
Aurora Summit medical centers performed 1,029 thoracic
surgical procedures.

According to U.S. News & World Report, Aurora received
the ‘best’ ranking for survival 30 days after thoracic
surgery, as well as the ‘best’ ranking for preventing
prolonged hospitalizations.

The majority of lung cancer surgery (97.5 percent)
performed at Aurora Grafton, Aurora Summit and
Aurora St. Luke’s in 2016 were Video-Assisted Procedures
(VATS). This is a minimally invasive technique used
when appropriate to yield the best possible outcome
for each patient.
VATS also may be used with a robotic technique. Minimally
invasive surgery has been shown to decrease length of
stay, as well as postoperative complication rates. Aurora
Health Care is able to accommodate the many patients
who desire a minimally invasive approach.

Aurora Health Care is proud to provide a highly qualified
and effective treatment team for our lung cancer patients.
For example, AHC’s William Tisol, MD, leads one of the
busiest robotic assisted thoracic surgery practices in
the world. Aurora Medical Center in Grafton serves as a
case observation center for the state-of-the-art Intuitive
Surgical da Vinci XI® surgical system. Surgeons and
their teams come from all over the country to observe
robotic assisted thoracic surgery. Aurora Medical Center
at Grafton is 1 of 10 approved thoracic robotic surgery
mentor sites in North America and 1 of 2 in the Midwest
hosting over 50 guests per year. Joining our lung cancer
treatment team and our nationally recognized robotic
assisted thoracic surgery program is David Demos, MD,
from Stanford University Hospital. ■
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NCORP update
On August 1, Aurora began its fourth

year as a National Cancer Institute’s (NCI)
Community Oncology Research Program,
or NCORP.
The NCI has awarded Aurora Research
Institute more than $200,000 beyond
Neha Glandt
its projected $755,000 annual grant.
Research Program
This is the fourth year in a row that NCI
Administrator
has increased the grant award to Aurora
NCI Community
NCORP. Aurora is projected to receive
Oncology Research
Program (NCORP)
more than $4 million by the time its
Aurora Research
five-year NCORP grant cycle ends in
Institute
2019. Thomas Saphner, MD, and Michael
Thompson, MD, PhD, serve as principal investigators for
Aurora NCORP.
Aurora is one of
34 sites nationwide
participating in
NCORP, which
A program of the National Cancer Institute
brings clinical
of the National Institutes of Health
cancer trials to
people in their own communities. Doing so means that a
more diverse patient population can participate in studies
in “real world” health care settings close to home. This
expanded access to clinical trials, in turn, generates more
broadly applicable evidence that can improve patient
outcomes and reduce cancer disparities. ■

Dr. Virani receiving his jersey.
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Aurora caregivers recognized
Thirteen Aurora Health Care physicians were
recognized by the NCI for being high oncology
clinical trial enrollers at the NCORP Principal
Investigators and Administrators Annual Meeting.
They each received a certificate from the NCI
recognizing their achievement at Aurora Cancer
Care’s Annual All-Oncology Meeting in September.
Shamsuddin Virani, MD, received a Platinum Award
for accruing 54 patients to NCI clinical trials since
Aurora Research Institute received its initial NCORP
grant in August 2014. In addition to a certificate,
principal investigator Dr. Tom Saphner presented Dr.
Virani with a personalized jersey for his role as the
highest accruing investigator.
Michael Mullane, MD, received a Gold Award for his
40 accruals.
The following received Appreciation Awards for
accruing between 11 and 19 patients over the past
three years: George Bobustuc, MD, Osama Halaweh,
MD, John Maul, MD, Ubaid Nawaz, MD, Dhimant Patel,
MD, Rubina Qamar, MD, Gilberto Rodrigues, MD,
Cheruppolil Santhosh-Kumar, MD, Tom Saphner, MD,
Corey Shamah, MD, Judy Tjoe, MD

Investigators, who enrolled at least one patient to a NCORP trial, present at the All Oncology Meeting.

Changing the face of cancer survivorship
Through her research program,

Dawn Groshek
Foundation
Development
Officer
Aurora Health Care
Foundation

Judy Tjoe, MD,
Medical Director,
Aurora Health Care

medical director Judy Tjoe, MD, is
dedicated to changing the face of breast
cancer care and survivorship through
Translational Oncology Research: Quest
for Understanding & Exploration, or
TORQUE. “Aurora Research Institute’s
breast cancer research program,
TORQUE, employs a ‘bedside-to-bench’
approach,” said Dr. Tjoe, a fellowshiptrained breast surgical oncologist.
TORQUE researchers aim to predict
which patients are susceptible to the
progression from noninvasive to invasive
disease. “TORQUE scientists leverage
patient data in the electronic health
record against a biorepository of tissue
and blood samples to find hidden clues,
or genetic biomarkers, that may increase
treatment effectiveness and improve
individual survivorship,” said Dr. Tjoe.

This collaborative atmosphere includes researchers in the
institute’s Biorepository and Specimen Resource Center
and industry partners, using residual tissue donated
by patients. They are studying the molecular makeup

of tumor cells, which improves understanding about
how cancer develops, allows discovery of those hidden
genetic biomarkers and spurs development of new
targeted drug therapies.
Care doesn’t stop after treatment
Under the TORQUE umbrella, the Team Phoenix
cancer survivorship program helps motivate women
cancer survivors to improve their quality of life. Under
medical guidance, they train for a triathlon, learning
best practices for removing physical and psychological
barriers for initiating and maintaining a regular exercise
routine after cancer treatment.
As part of the research component for Team Phoenix,
exercise physiologists and cardiologists would like to
work collaboratively to study how exercise affects
heart function after cardiotoxic breast cancer
treatments. Researchers also plan to investigate
ways to reduce cancer-related fatigue in patients
who have undergone treatment.
Studies conducted by TORQUE researchers are supported
by generous donors. If you would like to help advance
cancer research, please contact Dawn Groshek at dawn.
groshek@aurora.org. ■
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Lymphedema precautions outdated
Desiree Nelson, RN, BSN, OCN, Aurora Cancer Care

Traditionally, patients have received information on precautions after
breast surgery that was thought to reduce their risk for developing
lymphedema. These precautions were based on expert opinion, but
were not supported by evidence. This information caused undue
anxiety for the patients and the clinicians caring for them.
New research suggests that these precautions be abandoned unless the patient
has received a diagnosis of lymphedema from their doctor- The evidence-based
research determined that safe practices/procedures can include:
		
		
		
		

•
•
•
•

Blood pressure measurements on affected limb
Injections on affected limb
Venipunctures on affected limb
Flying without a compression sleeve

The Limb Alert section of Aurora’s Patient Identification policy will need to
be revised to reflect this system wide change.
True risk factors for developing lymphedema do exist. These risk factors include:
		
•
		•
		
•
		
•
		
•
		
•

Weight gain
Infections
Body Mass Index (BMI) ≥ 25
Axillary lymph node dissection
Radiation to the axilla
Older age at diagnosis

Patients can reduce their risk of lymphedema development by:
		
		
		
		
		

•
•
•
•
•

Maintaining a normal body weight
Minimizing the risk of infection in the involved area
Having physical therapy
Avoiding weight gain
Participating in regular exercise

Patients need this information to ensure proper care can be received.
Stay tuned for this important policy change. ■
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Aurora Cancer Care
receives 2017 ACCC
Innovator Award

Desiree Nelson, RN, BSN, OCN
Aurora Cancer Care

Aurora Cancer was recently
recognized by the Association of
Community Cancer Centers (ACCC)
with the 2017 Innovator Award for
the creation of Now Playing! drugspecific videos created to improve
chemotherapy patient education. ■

Deb Smith
Managing Editor, 		
News and Views
Aurora Cancer Care
deb.smith@aurora.org
Dr. Jim Weese receiving the Innovator Award from
Mark Soberman, ACCC President (left) and Christian Downs,
ACCC Executive Director (right).
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